Trials / No Longer Available
No Longer AvailableNCT05518838
Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Oblato, Inc. · Industry
- Sex
- All
- Age
- 13 Months – 18 Years
- Healthy volunteers
- —
Summary
To provide OKN-007 for compassionate use in patients with diffuse midline glioma, H3 K27-altered (DMG), including diffuse intrinsic pontine glioma (DIPG), pediatric and young adult patients with high-grade diffuse midline glioma will be treated under this Intermediate-sized expanded access treatment protocol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OKN-007 | OKN-007 is an intravenously administrated drug being developed as a novel anti-cancer therapy against gliomas. |
Timeline
- First posted
- 2022-08-29
- Last updated
- 2024-11-08
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05518838. Inclusion in this directory is not an endorsement.